Literature DB >> 30471183

High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor.

I M Rietveld1,2, W M Lijfering1,2,3, S le Cessie3,4, M H A Bos1,2, F R Rosendaal2,3, P H Reitsma1,2, S C Cannegieter2,3.   

Abstract

Essentials Elevated procoagulant levels are associated with an increased risk of venous thrombosis (VT). The dependency on concurrent increased factor levels and VT was analyzed in a large study. Factor VIII (FVIII) and von Willebrand factor (VWF) were associated with the highest VT risk. The risks for other procoagulant factor levels were largely explained by FVIII and VWF.
SUMMARY: Background Coagulation factors are essential for robust clot formation. However, elevated levels of procoagulant factors are associated with an increased risk of venous thrombosis (VT). The precise contribution of these factors to the development of VT is not yet understood. Objectives We determined the thrombosis risk for the highest levels of eight selected coagulation factors. Furthermore, we analyzed which of these coagulation factors had the strongest impact on the supposed association. Methods We used data of 2377 patients with a first VT and 2940 control subjects in whom fibrinogen, von Willebrand factor (VWF), factor II, FVII, FVIII, FIX, FX and FXI levels were measured. Results The odds ratios (ORs) for the various coagulation factor levels (> 99th percentile versus ≤ 25th percentile) varied between 1.8 and 4, except for FVIII (OR 23.0; 95% confidence interval [CI] 14.7-36.0) and VWF (OR 24.0; 95% CI 15.3-37.3). Adjustment for FVIII and VWF in a mediation analysis reduced the risks of the other factors to unity, with the exception of FIX and FXI (remaining ORs between 1.7 and 1.9). Conversely, the ORs for FVIII and VWF levels remained high after adjustment for all other procoagulant factors (FVIII: 16.0; 95% CI 9.7-26.3; VWF: 17.6; 95% CI 10.7-28.8). Conclusions Our results imply that the observed relationship between VT and coagulation factor levels can be largely explained by FVIII and VWF. FVIII and VWF levels were also associated with the highest VT risk.
© 2018 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  blood coagulation; case-control studies; factor VIII; venous thrombosis; von Willebrand factor

Mesh:

Substances:

Year:  2018        PMID: 30471183     DOI: 10.1111/jth.14343

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  25 in total

1.  A Case of Duodenal Resection and Duodenojejunostomy for Multiple Small Bowel Infarction in Patient With Inherited Thrombophilia and Vitamin K Antagonist Induced Critical Hypocoagulation.

Authors:  Badri Kobalava; Anzor Kvashilava; Giorgi Giorgobiani; Irina G Datikashvili-David; Nana Turava
Journal:  Cureus       Date:  2021-02-04

2.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

3.  Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation.

Authors:  Judicael Fazavana; Teresa M Brophy; Alain Chion; Niamh Cooke; Virginie Terraube; Justin Cohen; Chuenlei Parng; Debra Pittman; Orla Cunningham; Matthew Lambert; James S O'Donnell; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

4.  Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism.

Authors:  Magnus S Edvardsen; Kristian Hindberg; Ellen-Sofie Hansen; Vânia M Morelli; Thor Ueland; Pål Aukrust; Sigrid K Brækkan; Line H Evensen; John-Bjarne Hansen
Journal:  Blood Adv       Date:  2021-01-12

Review 5.  Hemophilia gene therapy: ushering in a new treatment paradigm?

Authors:  Lindsey A George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

6.  Hemostatic factors, inflammatory markers, and risk of incident venous thromboembolism: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Line H Evensen; Aaron R Folsom; James S Pankow; John-Bjarne Hansen; Matthew A Allison; Mary Cushman; Pamela L Lutsey
Journal:  J Thromb Haemost       Date:  2021-05-07       Impact factor: 16.036

7.  Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability.

Authors:  Huriye Ercan; Lisa-Marie Mauracher; Ella Grilz; Lena Hell; Roland Hellinger; Johannes A Schmid; Florian Moik; Cihan Ay; Ingrid Pabinger; Maria Zellner
Journal:  Cancers (Basel)       Date:  2021-05-08       Impact factor: 6.639

8.  Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia.

Authors:  Monica Sacco; Paola Ranalli; Stefano Lancellotti; Giovanna Petrucci; Alfredo Dragani; Bianca Rocca; Raimondo De Cristofaro
Journal:  Res Pract Thromb Haemost       Date:  2020-02-28

9.  Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19.

Authors:  Antoine Rauch; Julien Labreuche; Fanny Lassalle; Julien Goutay; Morgan Caplan; Leslie Charbonnier; Aurelien Rohn; Emmanuelle Jeanpierre; Annabelle Dupont; Alain Duhamel; Karine Faure; Marc Lambert; Eric Kipnis; Delphine Garrigue; Peter J Lenting; Julien Poissy; Sophie Susen
Journal:  J Thromb Haemost       Date:  2020-09-18       Impact factor: 16.036

10.  Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation.

Authors:  Lars L F G Valke; Laura H Bukkems; Wideke Barteling; Britta A P Laros-van Gorkom; Nicole M A Blijlevens; Ron A A Mathôt; Waander L van Heerde; Saskia E M Schols
Journal:  J Thromb Haemost       Date:  2020-10-21       Impact factor: 16.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.